142 related articles for article (PubMed ID: 8957673)
1. The development of cowpea mosaic virus as a potential source of novel vaccines.
Porta C; Spall VE; Lin T; Johnson JE; Lomonossoff GP
Intervirology; 1996; 39(1-2):79-84. PubMed ID: 8957673
[TBL] [Abstract][Full Text] [Related]
2. Development of cowpea mosaic virus-based vectors for the production of vaccines in plants.
Cañizares MC; Lomonossoff GP; Nicholson L
Expert Rev Vaccines; 2005 Oct; 4(5):687-97. PubMed ID: 16221070
[TBL] [Abstract][Full Text] [Related]
3. Intranasal immunization with a plant virus expressing a peptide from HIV-1 gp41 stimulates better mucosal and systemic HIV-1-specific IgA and IgG than oral immunization.
Durrani Z; McInerney TL; McLain L; Jones T; Bellaby T; Brennan FR; Dimmock NJ
J Immunol Methods; 1998 Nov; 220(1-2):93-103. PubMed ID: 9839930
[TBL] [Abstract][Full Text] [Related]
4. Potential of chimaeric plant virus particles as novel, stable vaccines.
Xu F; Jones TD; Rodgers PB
Dev Biol Stand; 1996; 87():201-5. PubMed ID: 8854018
[TBL] [Abstract][Full Text] [Related]
5. Development of cowpea mosaic virus as a high-yielding system for the presentation of foreign peptides.
Porta C; Spall VE; Loveland J; Johnson JE; Barker PJ; Lomonossoff GP
Virology; 1994 Aug; 202(2):949-55. PubMed ID: 8030255
[TBL] [Abstract][Full Text] [Related]
6. Human immunodeficiency virus type 1-neutralizing antibodies raised to a glycoprotein 41 peptide expressed on the surface of a plant virus.
McLain L; Porta C; Lomonossoff GP; Durrani Z; Dimmock NJ
AIDS Res Hum Retroviruses; 1995 Mar; 11(3):327-34. PubMed ID: 7786579
[TBL] [Abstract][Full Text] [Related]
7. Position-dependent processing of peptides presented on the surface of cowpea mosaic virus.
Taylor KM; Porta C; Lin T; Johnson JE; Barker PJ; Lomonossoff GP
Biol Chem; 1999 Mar; 380(3):387-92. PubMed ID: 10223342
[TBL] [Abstract][Full Text] [Related]
8. Influence of three-dimensional structure on the immunogenicity of a peptide expressed on the surface of a plant virus.
Taylor KM; Lin T; Porta C; Mosser AG; Giesing HA; Lomonossoff GP; Johnson JE
J Mol Recognit; 2000; 13(2):71-82. PubMed ID: 10822251
[TBL] [Abstract][Full Text] [Related]
9. Chimeric plant virus particles as immunogens for inducing murine and human immune responses against human immunodeficiency virus type 1.
Marusic C; Rizza P; Lattanzi L; Mancini C; Spada M; Belardelli F; Benvenuto E; Capone I
J Virol; 2001 Sep; 75(18):8434-9. PubMed ID: 11507188
[TBL] [Abstract][Full Text] [Related]
10. Immunogenic presentation of a conserved gp41 epitope of human immunodeficiency virus type 1 on recombinant surface antigen of hepatitis B virus.
Eckhart L; Raffelsberger W; Ferko B; Klima A; Purtscher M; Katinger H; Rüker F
J Gen Virol; 1996 Sep; 77 ( Pt 9)():2001-8. PubMed ID: 8810996
[TBL] [Abstract][Full Text] [Related]
11. Antigenic characteristics of rhinovirus chimeras designed in silico for enhanced presentation of HIV-1 gp41 epitopes [corrected].
Lapelosa M; Arnold GF; Gallicchio E; Arnold E; Levy RM
J Mol Biol; 2010 Apr; 397(3):752-66. PubMed ID: 20138057
[TBL] [Abstract][Full Text] [Related]
12. Immunogenic and antigenic dominance of a nonneutralizing epitope over a highly conserved neutralizing epitope in the gp41 envelope glycoprotein of human immunodeficiency virus type 1: its deletion leads to a strong neutralizing response.
Cleveland SM; Buratti E; Jones TD; North P; Baralle F; McLain L; McInerney T; Durrani Z; Dimmock NJ
Virology; 2000 Jan; 266(1):66-78. PubMed ID: 10612661
[TBL] [Abstract][Full Text] [Related]
13. Human Rhinovirus Presenting 4E10 Epitope of HIV-1 MPER Elicits Neutralizing Antibodies in Human ICAM-1 Transgenic Mice.
Yi G; Tu X; Bharaj P; Guo H; Zhang J; Shankar P; Manjunath N
Mol Ther; 2015 Oct; 23(10):1663-70. PubMed ID: 26061648
[TBL] [Abstract][Full Text] [Related]
14. Libraries of human rhinovirus-based HIV vaccines generated using random systematic mutagenesis.
Resnick DA; Smith AD; Zhang A; Geisler SC; Arnold E; Arnold GF
AIDS Res Hum Retroviruses; 1994; 10 Suppl 2():S47-52. PubMed ID: 7865333
[TBL] [Abstract][Full Text] [Related]
15. Chimeric rhinoviruses as tools for vaccine development and characterization of protein epitopes.
Arnold GF; Resnick DA; Smith AD; Geisler SC; Holmes AK; Arnold E
Intervirology; 1996; 39(1-2):72-8. PubMed ID: 8957672
[TBL] [Abstract][Full Text] [Related]
16. Development and analysis of recombinant BCG vector systems.
Fuerst TR; de la Cruz VF; Bansal GP; Stover CK
AIDS Res Hum Retroviruses; 1992 Aug; 8(8):1451-5. PubMed ID: 1466980
[No Abstract] [Full Text] [Related]
17. Cowpea mosaic virus-based vaccines.
Lomonossoff GP; Hamilton WD
Curr Top Microbiol Immunol; 1999; 240():177-89. PubMed ID: 10394721
[No Abstract] [Full Text] [Related]
18. Immunisation with foamy virus Bet fusion proteins as novel strategy for HIV-1 epitope delivery.
Mühle M; Hoffmann K; Löchelt M; Denner J
Immunol Res; 2013 May; 56(1):61-72. PubMed ID: 23440699
[TBL] [Abstract][Full Text] [Related]
19. Analysis of the ability of five adjuvants to enhance immune responses to a chimeric plant virus displaying an HIV-1 peptide.
McInerney TL; Brennan FR; Jones TD; Dimmock NJ
Vaccine; 1999 Mar; 17(11-12):1359-68. PubMed ID: 10195771
[TBL] [Abstract][Full Text] [Related]
20. Bovine papillomavirus-like particles presenting conserved epitopes from membrane-proximal external region of HIV-1 gp41 induced mucosal and systemic antibodies.
Zhai Y; Zhong Z; Zariffard M; Spear GT; Qiao L
Vaccine; 2013 Nov; 31(46):5422-9. PubMed ID: 24055348
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
